China has approved the very first patent for the country’s coronavirus, the Chinese media reported, paving the way for local inoculation against the disease.
The vaccine, named AD5-NCOV, was developed by the company Biopharmaceutique Cansino Biologics in partnership with a team led by a Chinese military expert in infectious diseases.
Directed by Ms. Chen Wei, researcher at the Academy’s Institute of Military Medicine, the team has developed the recombinant vaccine against COVID-19, with a vector for modified defective adenovirus. In March, the vaccine became the first approved vaccine in China for clinical trials.
In a declaration to the Global Times, the Chinese company said that the patent reflected the efficiency and security of the vaccine, as well as the safeguarding of intellectual property rights (DPI) of Cansino.
The vaccine has now completed the phase 1 and phase 2 clinical trials, which checked its safety and immunogenicity, the newspaper reported.
Saudi Arabia and Mexico will soon start the phase III clinical trials of the Cansino vaccine. Chinese society also hopes to start phase III tests in Russia, Brazil and Chile. The results of the first two test phases are promising.
